BNP Paribas Financial Markets’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $43.2K | Sell |
6,990
-2,898
| -29% | -$15.9K | ﹤0.01% | 4955 |
|
|
2026
Q1 | $44.3K | Buy |
9,888
+334
| +3% | +$1.67K | ﹤0.01% | 4761 |
|
|
2025
Q4 | $50.4K | Sell |
9,554
-448
| -4% | -$2.25K | ﹤0.01% | 4682 |
|
|
2025
Q3 | $52.8K | Sell |
10,002
-121,943
| -92% | -$773K | ﹤0.01% | 4582 |
|
|
2025
Q2 | $749K | Buy |
+131,945
| New | +$751K | ﹤0.01% | 3085 |
|
|
2025
Q1 | – | Sell |
-1
| Closed | -$6 | – | 5374 |
|
|
2024
Q4 | $6 | Buy |
+1
| New | +$6 | ﹤0.01% | 5370 |
|
|
2022
Q4 | – | Sell |
-4
| Closed | -$12 | – | 4026 |
|
|
2022
Q3 | $12 | Sell |
4
-1
| -20% | -$4 | ﹤0.01% | 4705 |
|
|
2022
Q2 | $25 | Hold |
5
| – | – | ﹤0.01% | 4052 |
|
|
2022
Q1 | $38 | Sell |
5
-74,176
| -100% | -$509K | ﹤0.01% | 4113 |
|
|
2021
Q4 | $625K | Buy |
74,181
+74,175
| +1,236,250% | +$1.36M | ﹤0.01% | 2894 |
|
|
2021
Q3 | $178 | Buy |
6
+1
| +20% | +$32 | ﹤0.01% | 3954 |
|
|
2021
Q2 | $187 | Sell |
5
-759
| -99% | -$31K | ﹤0.01% | 4000 |
|
|
2021
Q1 | $35.9K | Buy |
764
+315
| +70% | +$17.4K | ﹤0.01% | 3682 |
|
|
2020
Q4 | $17.6K | Sell |
449
-122
| -21% | -$4.16K | ﹤0.01% | 3868 |
|
|
2020
Q3 | $14.6K | Buy |
571
+478
| +514% | +$30.1K | ﹤0.01% | 3911 |
|
|
2020
Q2 | $6.76K | Sell |
93
-558
| -86% | -$38.6K | ﹤0.01% | 3881 |
|
|
2020
Q1 | $34.2K | Buy |
651
+332
| +104% | +$22.2K | ﹤0.01% | 3724 |
|
|
2019
Q4 | $26.1K | Buy |
319
+117
| +58% | +$8.26K | ﹤0.01% | 3929 |
|
|
2019
Q3 | $11.4K | Buy |
202
+1
| +0.5% | +$75 | ﹤0.01% | 4128 |
|
|
2019
Q2 | $24K | Sell |
201
-59
| -23% | -$9.89K | ﹤0.01% | 3832 |
|
|
2019
Q1 | $47.9K | Buy |
260
+259
| +25,900% | +$46.3K | ﹤0.01% | 3516 |
|
|
2018
Q4 | $214 | Sell |
1
-35
| -97% | -$7.63K | ﹤0.01% | 4092 |
|
|
2018
Q3 | $11.5K | Sell |
36
-14
| -28% | -$4.97K | ﹤0.01% | 3664 |
|
|
2018
Q2 | $19.8K | Sell |
50
-183
| -79% | -$80K | ﹤0.01% | 3502 |
|
|
2018
Q1 | $83.7K | Buy |
233
+1
| +0.4% | +$372 | ﹤0.01% | 3288 |
|
|
2017
Q4 | $91.8K | Buy |
232
+138
| +147% | +$57.1K | ﹤0.01% | 3348 |
|
|
2017
Q3 | $40.3K | Sell |
94
-7
| -7% | -$1.88K | ﹤0.01% | 3259 |
|
|
2017
Q2 | $16.2K | Buy |
+101
| New | +$13.8K | ﹤0.01% | 3772 |
|
|
2016
Q2 | – | Sell |
-59
| Closed | -$3.75K | – | 3565 |
|
|
2016
Q1 | $3.75K | Sell |
59
-25
| -30% | -$1.66K | ﹤0.01% | 2316 |
|
|
2015
Q4 | $7.02K | Sell |
84
-19
| -18% | -$1.91K | ﹤0.01% | 3433 |
|
|
2015
Q3 | $10.4K | Buy |
+103
| New | +$13.7K | ﹤0.01% | 3421 |
|
Other funds holding ABEO
NCM
CCC
ACM
OIA
AIC
BNP Paribas Financial Markets's ABEO Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Abeona Therapeutics (ABEO) stake by 29% in Q2 2026, selling an estimated $15.9K and leaving 6,990 shares worth $43.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4955.
BNP Paribas Financial Markets first reported a position in ABEO in Q3 2015 and has held it in 31 quarters since. The position peaked at $749K in Q2 2025. 113 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.
- BNP Paribas Financial Markets held 6,990 shares of Abeona Therapeutics worth $43.2K as of Q2 2026.
- BNP Paribas Financial Markets sold 2,898 Abeona Therapeutics shares in Q2 2026, an estimated $15.9K.
- Abeona Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4955 holding.
- BNP Paribas Financial Markets first reported a position in Abeona Therapeutics in Q3 2015 and has held it in 31 quarters since.
- BNP Paribas Financial Markets's Abeona Therapeutics position peaked at $749K in Q2 2025.
- 113 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.